Brain Activity Flow Patterns Analysis Using Evoked Response Potentials in Youth With ADHD, Bipolar Disorder, or Autism Spectrum Disorders: A Preliminary Study
The study aims to evaluate whether or not an EEG (a type of brain scan) is useful in diagnosing youth with either ADHD, BPD, ASD. Youth with ADHD, BPD, ASD, and healthy controls (without ADHD, BPD, and ASD) will undergo an EEG, and the results will be analyzed using brain activity flow pattern analysis (BAFPA). Twenty subjects with each disorder and twenty without any of the disorders under study (controls) will be evaluated. All subjects will be comprehensively assessed with structured diagnostic interviews and neuropsychological testing. All EEG analyses will be conducted under blind conditions. Conditional probability and receiver operating characteristic (ROC) analyses will examine the diagnostic utility of the EEG scan, using the clinical diagnosis of ASD as the gold standard.
Attention Deficit Hyperactivity Disorder
Autism Spectrum Disorder
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Brain Activity Flow Patterns Analysis Using Evoked Response Potentials in Youth With ADHD, Bipolar Disorder, or Autism Spectrum Disorders: A Preliminary Study|
- Agreement between clinical diagnoses and the results of brain activity flow pattern analysis (BAFPA). [ Time Frame: Baseline ] [ Designated as safety issue: No ]Subjects will undergo clinical diagnostic interviews and a comprehensive neuropsychological assessment, and then complete 1 EEG scan of approximately 1 hour. The results of the BAFPA will be compared to the results of the clinical diagnostic interviews.
|Study Start Date:||March 2011|
|Study Completion Date:||November 2012|
|Primary Completion Date:||November 2012 (Final data collection date for primary outcome measure)|
Youth diagnosed with ADHD.
Youth diagnosed with an Autism Spectrum Disorder (ASD).
Youth diagnosed with Bipolar Disorder.
Youth not diagnosed with any psychiatric/psychological disorder.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01506232
|United States, Massachusetts|
|Massachusetts General Hospital|
|Cambridge, Massachusetts, United States, 02138|
|Principal Investigator:||Gagan Joshi, MD||Massachusetts General Hospital|